Opinion
Video
Efficacy and Safety of Oral SERDs and Other Endocrine Therapies in ER+/HER2- Metastatic Breast Cancer
Experts explore the efficacy and safety profiles of elacestrant, an oral selective estrogen receptor degrader (SERD), and other options for endocrine therapy. The panelists also discuss clinical trial insights, progression-free survival rates, and tolerability, highlighting outcomes and advances in metastatic breast cancer treatment.
This is a video synopsis/summary of a Peer Exchange featuring Mabel Mardones, MD; Rena Callahan, MD; William Gradishar, MD; and Gregory Vidal, MD, PhD.
Mardones discusses the efficacy and safety of oral SERDs with experts Callahan, Gradishar, and Vidal. Callahan highlights the favorable efficacy of oral elacestrant, which shows double median progression-free survival (PFS) and triple landmark PFS at 1 year compared with standard therapy. Gradishar notes elacestrant’s favorable safety profile, which is well tolerated with minimal dosing adjustments.
Vidal compares elacestrant with fulvestrant, emphasizing elacestrant’s oral administration, superior efficacy––especially in ESR1 mutations––and a similar safety profile. The discussion underscores elacestrant’s promising role in metastatic breast cancer treatment, providing valuable insights for clinicians.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
